title: Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.
abstract: Varicose veins (VVs) are a common venous disease of the lower extremity characterized by incompetent valves, venous reflux, and dilated and tortuous veins. If untreated, VVs could lead to venous thrombosis, thrombophlebitis and chronic venous leg ulcers. Various genetic, hormonal and environmental factors may lead to structural changes in the vein valves and make them incompetent, leading to venous reflux, increased venous pressure and vein wall dilation. Prolonged increases in venous pressure and vein wall tension are thought to increase the expression/activity of matrix metalloproteinases (MMPs). Members of the MMPs family include collagenases, gelatinases, stromelysins, matrilysins, membrane- type MMPs and others. MMPs are known to degrade various components of the extracellular matrix (ECM). MMPs may also affect the endothelium and vascular smooth muscle, causing changes in the vein relaxation and contraction mechanisms. Endothelial cell injury also triggers leukocyte infiltration, activation and inflammation, which lead to further vein wall damage. The vein wall dilation and valve dysfunction, and the MMP activation and superimposed inflammation and fibrosis would lead to progressive venous dilation and VVs formation. Surgical ablation is an effective treatment for VVs, but may be associated with high recurrence rate, and other less invasive approaches that target the cause of the disease are needed. MMP inhibitors including endogenous tissue inhibitors (TIMPs) and pharmacological inhibitors such as zinc chelators, doxycycline, batimastat and marimastat, have been used as diagnostic and therapeutic tools in cancer, autoimmune and cardiovascular disease. However, MMP inhibitors may have side effects especially on the musculoskeletal system. With the advent of new genetic and pharmacological tools, specific MMP inhibitors with fewer undesirable effects could be useful to retard the progression and prevent the recurrence of VVs.
authors: Vascular Surgery Research Laboratory, Division of Vascular and Endovascular Surgery, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA 02115, USA.
authors: Arda
authors: A
authors: Kucukguven
authors: Raouf A
authors: RA
authors: Khalil
mesh_terms: D002465:Cell Movement; D003872:Dermatitis / Q000188:drug therapy / Q000201:enzymology; D004108:Dilatation, Pathologic; D005260:Female; D006801:Humans; D006874:Hydrostatic Pressure; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors / Q000627:therapeutic use*; D020782:Matrix Metalloproteinases / Q000502:physiology*; D012594:Scleroderma, Localized / Q000188:drug therapy / Q000201:enzymology; D013924:Thrombophlebitis / Q000188:drug therapy / Q000201:enzymology; D014648:Varicose Veins / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology; D014661:Vasoconstriction; D014945:Wound Healing
chemical_list: D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases